H. Lundbeck
Market Cap
ø48.2b
Last Updated
2019/08/24 20:51 UTC
Data Sources
Company Financials +
Executive Summary
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally.
Snowflake
Fundamentals
Flawless balance sheet, good value and pays a dividend.
Similar Companies
Share Price & News
How has H. Lundbeck's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-10.0%
CPSE:LUN
0.5%
DK Pharmaceuticals
0.9%
DK Market
1 Year Return
-35.4%
CPSE:LUN
5.4%
DK Pharmaceuticals
3.9%
DK Market
LUN underperformed the Pharmaceuticals industry which returned 5.3% over the past year.
LUN underperformed the Market in Denmark which returned 3.9% over the past year.
Share holder returns
| LUN | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.0% | 0.5% | 0.9% |
| 30 Day | -6.3% | 2.1% | 1.2% |
| 90 Day | -10.5% | 5.0% | 3.7% |
| 1 Year | -32.7%-35.4% | 11.2%5.4% | 7.0%3.9% |
| 3 Year | -5.2%-11.8% | 24.2%10.4% | 31.3%20.5% |
| 5 Year | 118.7%103.4% | 31.5%9.9% | 68.8%44.1% |
Price Volatility Vs. Market
How volatile is H. Lundbeck's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Can We Expect From H. Lundbeck A/S's (CPH:LUN) Earnings Over The Next Year?1 week ago | Simply Wall St
How To Gain With H. Lundbeck A/S (CPH:LUN)3 weeks ago | Simply Wall St
Should H. Lundbeck A/S (CPH:LUN) Be Your Next Stock Pick?Valuation
Is H. Lundbeck undervalued based on future cash flows and its price relative to the stock market?
47%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
H. Lundbeck's share price is below the future cash flow value, and at a moderate discount (> 20%).
H. Lundbeck's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
H. Lundbeck is good value based on earnings compared to the Europe Pharmaceuticals industry average.
H. Lundbeck is good value based on earnings compared to the Denmark market.
Price Based on Expected Growth
H. Lundbeck is poor value based on expected growth next year.
Price Based on Value of Assets
H. Lundbeck is overvalued based on assets compared to the Europe Pharmaceuticals industry average.
Next Steps
Future Growth
How is H. Lundbeck expected to perform in the next 1 to 3 years based on estimates from 14 analysts?
7.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
H. Lundbeck's revenue is expected to grow by 1% yearly, however this is not considered high growth (20% yearly).
H. Lundbeck's earnings are expected to grow by 7.8% yearly, however this is not considered high growth (20% yearly).
H. Lundbeck's revenue growth is positive but not above the Denmark market average.
H. Lundbeck's earnings growth is positive but not above the Denmark market average.
H. Lundbeck's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Earnings per Share Growth Estimates
Future Return on Equity
H. Lundbeck is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Next Steps
Past Performance
How has H. Lundbeck performed over the past 5 years?
53.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
H. Lundbeck has delivered over 20% year on year earnings growth in the past 5 years.
H. Lundbeck's 1-year earnings growth is negative, it can't be compared to the 5-year average.
H. Lundbeck's 1-year earnings growth is negative, it can't be compared to the Europe Pharmaceuticals industry average.
Return on Equity
H. Lundbeck has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
Return on Assets
H. Lundbeck used its assets more efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.
Return on Capital Employed
H. Lundbeck has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
Next Steps
Financial Health
How is H. Lundbeck's financial position?
Financial Position Analysis
H. Lundbeck is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
H. Lundbeck's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
H. Lundbeck's level of debt (4.8%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (16.1% vs 4.8% today).
Debt is well covered by operating cash flow (531.8%, greater than 20% of total debt).
H. Lundbeck earns more interest than it pays, coverage of interest payments is not a concern.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 13.2x debt.
Next Steps
Dividend
What is H. Lundbeck's current dividend yield, its reliability and sustainability?
3.46%
Expected Dividend Yield
Dividend Yield and Payments Analysis
H. Lundbeck's pays a higher dividend yield than the bottom 25% of dividend payers in Denmark (1.7%).
H. Lundbeck's dividend is below the markets top 25% of dividend payers in Denmark (5%).
Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Dividends per share have increased over the past 10 years.
Current Payout to Shareholders
Dividends paid are covered by earnings (1.4x coverage).
Future Payout to Shareholders
Dividends after 3 years are expected to be well covered by earnings (2.2x coverage).
Next Steps
Management
What is the CEO of H. Lundbeck's salary, the management and board of directors tenure and is there insider trading?
1.4yrs
Average management tenure
CEO
Deborah Dunsire (57yo)
1.1yrs
Tenure
ø13,700,000
Compensation
Dr. Deborah Dunsire, M.D. serves as Chief Executive Officer and President at H. Lundbeck A/S since July, 2018 and served as its Interim Executive Vice President of R&D since January 2019 until February 201 ...
CEO Compensation Analysis
Deborah's remuneration is about average for companies of similar size in Denmark.
Insufficient data for Deborah to compare compensation growth.
Management Age and Tenure
1.4yrs
Average Tenure
57yo
Average Age
The average tenure for the H. Lundbeck management team is less than 2 years, this suggests a new team.
Board Age and Tenure
1.6yrs
Average Tenure
53yo
Average Age
The average tenure for the H. Lundbeck board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Deborah Dunsire (57yo)
President & CEO
- Tenure: 1.1yrs
- Compensation: ø13.70m
Lars Bang (57yo)
Executive Vice President of Product Development & Supply
- Tenure: 0.6yrs
- Compensation: ø8.50m
Anders Götzsche (52yo)
Executive VP & CFO
- Tenure: 12.3yrs
- Compensation: ø12.30m
Ole Chrintz (61yo)
Senior Vice President of International Markets
- Tenure: 0.0yrs
Jacob Tolstrup (47yo)
Executive Vice President of Commercial Operations
- Tenure: 1.8yrs
- Compensation: ø7.80m
Helle Juhl
Executive of Human Resources
- Tenure: 0.0yrs
Peter Anastasiou (49yo)
Executive Vice President of North America
- Tenure: 1.8yrs
Anders Schroll
Vice President of Corporate Communications & Global Public Affairs
- Tenure: 0.0yrs
Palle Olesen
Chief Specialist & VP of Investor Relations
- Tenure: 0.0yrs
Johan Luthman (63yo)
Executive Vice President of R&D
- Tenure: 0.4yrs
Board Members
Jeremy Levin (66yo)
Director
- Tenure: 2.6yrs
Henrik Andersen (52yo)
Director
- Tenure: 1.4yrs
Lars Rasmussen (60yo)
Chairman
- Tenure: 3.3yrs
Lene Skole-Sørensen (60yo)
Deputy Chairman
- Tenure: 4.6yrs
Jeff Berkowitz (53yo)
Director
- Tenure: 1.4yrs
Lars Holmqvist (60yo)
Director
- Tenure: 4.6yrs
Henrik Jensen (50yo)
Employee Representative Director
- Tenure: 1.6yrs
Rikke Andreasen (48yo)
Employee Representative Director
- Tenure: 1.4yrs
Ludovic Otterbein (46yo)
Employee Representative Director
- Tenure: 1.4yrs
Company Information
H. Lundbeck A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: H. Lundbeck A/S
- Ticker: LUN
- Exchange: CPSE
- Founded: 1915
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø48.202b
- Shares outstanding: 198.77m
- Website: https://www.lundbeck.com
Number of Employees
Location
- H. Lundbeck A/S
- Ottiliavej 9
- Valby
- Capital Region of Denmark
- 2500
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HLUK.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 1999 |
| LUN | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Ordinary Shares | DK | DKK | Jun 1999 |
| LDB | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 1999 |
| 0ND5 | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | DKK | Jun 1999 |
| LUNC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | DKK | Jun 1999 |
| HLUY.Y | OTCPK (Pink Sheets LLC) | SPONS ADR L 1 | US | USD | May 2012 |
Biography
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/24 20:51 |
| End of Day Share Price | 2019/08/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.